The Blue Venture Fund (formerly BlueCross BlueShield Venture Partners) is a corporate venture capital collaboration among participating Blue Cross Blue Shield companies, the Blue Cross Blue Shield Association, and Sandbox Industries. It invests in healthcare technology, healthcare services, and clinical sciences companies to drive better health outcomes.
57% of their portfolio is in Healthcare. Deal activity increased 200% year-over-year (6 deals in the last 12 months). Average disclosed round size is $43.2M (across 35 rounds with reported amounts).
Portfolio
37
Fund Size
—
Top Stage
Series A
Last 12 Mo
5
Team
John Banta
President & Managing Director of the Blue Venture Funds and the President of the fund’s General Partner
Chris Zock
Managing Director
Dan Philips
Managing Director
Emir Sandhu
Managing Director
Jeff Carroll
Managing Director
Kelsey Maguire
Managing Director
Matt Downs
Managing Director
Tommy Hawes
Managing Director
Mark Bartlett
Venture Partner
Amanda Harlan
Vice President
Kelly Carlquist
Vice President
Liam McDonald
Vice President
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Big Health | Unknown | $23.7M | Feb 2026 |
 Origin | Series B | — | Jan 2026 |
 Nest Health | Series A | $12.5M | Oct 2025 |
 Daymark Health | Series A | $20M | Sep 2025 |
| DDaymark | Series A | $20M | Sep 2025 |
 Ultromics | Series C | $55M | Jul 2025 |
 Upward Health | Series C | — | Jan 2025 |
 Fort Health | Series A | $5.5M | Nov 2024 |
 Humata Health | Unknown | $25M | Jun 2024 |
 Lumeris | Growth | $100M | Apr 2024 |
 Sempre Health | Series B | $20M | Sep 2023 |
 Limber Health | Series A | $11M | Oct 2022 |
| LLimber | Series A | $11M | Oct 2022 |
 Shark Solutions | Growth | — | Oct 2022 |
 PATH | Series A | $30M | Sep 2022 |
 Abacus Insights | Series C | $28M | Jun 2022 |
 Somatus | Series E | $325M | Feb 2022 |
| Abacus Insights | Series C | $28M | Jan 2022 |
 Reflaunt | Series A | — | Jan 2022 |
| Somatus | Series E | $325M | Jan 2022 |
 Wayspring | Growth | $75M | Sep 2021 |
| Ultromics | Series B | $33M | Aug 2021 |
| BBluestone Physician Services | Unknown | — | Aug 2021 |
| Sempre Health | Series B | — | Jun 2021 |
 SEMPRE | Series A | $14.3M | Jun 2021 |
Top Co-Investors
Last updated: 8 September 2026